Last reviewed · How we verify
Kedbumin 25%
Kedbumin 25% is a Plasma protein fraction / Human serum albumin Small molecule drug developed by Kedrion S.p.A.. It is currently FDA-approved for Hypoproteinemia and hypovolemia in critically ill patients, Acute blood loss and hemorrhagic shock, Severe burns. Also known as: Albumin (Human) 25%.
Kedbumin 25% is a human serum albumin solution that restores and maintains oncotic pressure and serves as a carrier protein for endogenous and exogenous substances in the bloodstream.
Kedbumin 25% is a treatment that has been studied in clinical trials for various conditions, including COVID-19, coronary disease, shock, cardiogenic shock, renal failure, and stroke. It is administered in combination with other interventions, such as Byetta (exenatide) and Conoxia (oxygen), as part of these trials.
At a glance
| Generic name | Kedbumin 25% |
|---|---|
| Also known as | Albumin (Human) 25% |
| Sponsor | Kedrion S.p.A. |
| Drug class | Plasma protein fraction / Human serum albumin |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Hematology |
| Phase | FDA-approved |
Mechanism of action
Human serum albumin is a plasma protein that maintains colloid osmotic pressure, regulates fluid distribution between intravascular and extravascular compartments, and transports various substances including hormones, fatty acids, and drugs. Kedbumin 25% is a concentrated albumin preparation used to restore blood volume and plasma protein levels in patients with hypoproteinemia or acute blood loss. It helps maintain hemodynamic stability and tissue perfusion in critically ill patients.
Approved indications
- Hypoproteinemia and hypovolemia in critically ill patients
- Acute blood loss and hemorrhagic shock
- Severe burns
- Liver cirrhosis with ascites
- Nephrotic syndrome
Common side effects
- Hypervolemia / fluid overload
- Hypersensitivity reactions
- Fever
- Chills
- Nausea
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Panhematin for Prevention of Acute Attacks of Porphyria (PHASE2)
- Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2 (PHASE3)
- Comparative Study Between Sclerosing Agents Used in Treatment of Vascular Malformation (NA)
- A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis (PHASE2)
- Intravenous Immunoglobulin and Prednisolone for RPL After ART. (PHASE2)
- Autoimmune Basis for Postural Tachycardia Syndrome (NA)
- Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kedbumin 25% CI brief — competitive landscape report
- Kedbumin 25% updates RSS · CI watch RSS
- Kedrion S.p.A. portfolio CI
Frequently asked questions about Kedbumin 25%
What is Kedbumin 25%?
How does Kedbumin 25% work?
What is Kedbumin 25% used for?
Who makes Kedbumin 25%?
Is Kedbumin 25% also known as anything else?
What drug class is Kedbumin 25% in?
What development phase is Kedbumin 25% in?
What are the side effects of Kedbumin 25%?
Related
- Drug class: All Plasma protein fraction / Human serum albumin drugs
- Manufacturer: Kedrion S.p.A. — full pipeline
- Therapeutic area: All drugs in Critical Care / Hematology
- Indication: Drugs for Hypoproteinemia and hypovolemia in critically ill patients
- Indication: Drugs for Acute blood loss and hemorrhagic shock
- Indication: Drugs for Severe burns
- Also known as: Albumin (Human) 25%
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing